Uluslararası HastaDuyurularİletişim
HACETTEPE ÜNİVERSİTESİHASTANELERİ
Randevu Al
TR
  1. Ana Sayfa
  2. Doktorlar
  3. Prof. Dr. Pervin Hürmüz
Prof. Dr. Pervin Hürmüz

Prof. Dr.

Pervin Hürmüz

Radyasyon Onkolojisi · Onkoloji Hastanesi

Randevu Al0312 305 29 00

Hakkında

2001'de Hacettepe Üniversitesi Tıp Fakültesi'nden (İngilizce) mezun oldu. 2008'de Hacettepe Üniversitesi Tıp Fakültesi Radyasyon Onkolojisi Anabilim Dalında uzmanlık eğitimini tamamladı. Devlet hizmet yükümlülüğü kapsamında Trabzon Numune Eğitim ve Araştırma Hastanesinde çalıştı. 2010 yılında başasistan olarak Ankara Atatürk Eğitim ve Araştırma Hastanesinde çalıştı. Şubat 2011'den itibaren Hacettepe Üniversitesi Tıp Fakültesi Radyasyon Onkolojisi Anabilim Dalı'nda uzman olarak çalışmaya başladı. 2012'de yardımcı doçent oldu. 2008'de İngiltere'de St James' University Hospital'da üç boyutlu konformal brakiterapi ve gastrointestinal sistem tümörleri ile ilgili çalışmalarda bulundu.

Eğitim

  1. Yüksek lisans — Radyasyon Onkolojisi
    Radyasyon Onkolojisi
  2. 2001
    Tıp Fakültesi (İngilizce)
    Hacettepe Üniversitesi
  3. 1995
    Atatürk Lisesi

Yayınlar

Kaynak: Hacettepe Üniversitesi Akademik Veri Yönetim Sistemi (AVESİS) · Tüm yayınlar (115) ↗

Makaleler 76

  1. Stereotactic body radiotherapy for bone-only oligometastatic bladder Cancer: a multi-institutional experienceTilki B., Guler O. C., Demirhan B., HÜRMÜZ P., Elmalı A., KUMRU T., et al.Clinical and Translational Radiation Oncology, cilt.60, 2026 (SCI-Expanded, Scopus)
  2. Long term outcomes of prostate cancer patients aged 55 years or younger treated with definitive radiotherapy: Trod 09-005 studyBeduk Esen C. S., Elmali A., Demirhan B., Guler O. C., Dincer S. T., ALSAN ÇETİN İ., et al.Strahlentherapie und Onkologie, cilt.202, sa.2, ss.139-148, 2026 (SCI-Expanded, Scopus)
  3. Impact of Adjuvant Radiotherapy and Mitotane on Survival in Localized Adrenocortical Carcinoma: A Retrospective Cohort StudyElmali A., Guler O. C., ÖZYİĞİT G., HÜRMÜZ P., Onal C.International Journal of Urology, cilt.33, sa.1, 2026 (SCI-Expanded, Scopus)
  4. Factors influencing the use of hypofractionated radiotherapy in prostate cancer: a nationwide survey of radiation oncologists in Turkiye (TROD 09—008)Akgun Z., HÜRMÜZ P., İğdem Ş.Clinical and Translational Oncology, 2026 (SCI-Expanded, Scopus)
  5. The impact of malnutrition in the radiotherapy pathway in geriatric patients in the onco-surgical settings on behalf of the Turkish Society for Radiation Oncology Study Group (TROD 12-04)YÜRÜT ÇALOĞLU V., Serarslan A., KANYILMAZ G., Saglam E. K., HÜRMÜZ P., ÇOLPAN ÖKSÜZ D., et al.EJSO, cilt.51, sa.8, 2025 (SCI-Expanded, Scopus)
  6. Comments on "Analysis of patients with locally advanced rectal cancer given neoadjuvant radiochemotherapy with or without RT dose intensification: A multicenter retrospective study ATLANTIS part I"ÖZYÜREK Y., HÜRMÜZ P., YILDIZ F.RADIOTHERAPY AND ONCOLOGY, cilt.207, 2025 (SCI-Expanded, Scopus)
  7. Translation, Cross-Cultural Adaptation, and Psychometric Validation of the Turkish Version of the "Expanded Prostate Cancer Index Composite (EPIC)" in Prostate Cancer PatientsTİLKİ B., HÜRMÜZ P., YÜCE D., ÖZYİĞİT G., Akyol F.PROSTATE, cilt.85, sa.7, ss.710-718, 2025 (SCI-Expanded, Scopus)
  8. Evaluating the impact of cardiac substructure dosimetric parameters on survival in lung cancer patients undergoing postoperative radiotherapyYilmaz M. T., HÜRMÜZ P., GÜRLEK E., YILDIZ D., CENGİZ M.STRAHLENTHERAPIE UND ONKOLOGIE, cilt.201, sa.4, ss.452-462, 2025 (SCI-Expanded, Scopus)
  9. Prognostic Impact of Low Muscle Mass and Inflammatory Markers in Stage III Nonsmall Cell Lung Cancer Turkish Oncology Group and Turkish Society of Radiation Oncology Thoracic Cancer Study Group (08-005)Gumustepe E., Yavas G., Kirakli E. K., DİNÇBAŞ H. F., Dilek N., HÜRMÜZ P., et al.AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, cilt.48, sa.2, ss.67-74, 2025 (SCI-Expanded, Scopus)
  10. Multi-institutional analysis of extracranial oligometastatic colorectal cancer patients treated with stereotactic body radiation therapy: TROD 02-008 studyGuler O. C., HÜRMÜZ P., ATALAR B., Guney Y., Saglam E. K., AKYÜREK S., et al.STRAHLENTHERAPIE UND ONKOLOGIE, cilt.200, ss.958-966, 2024 (SCI-Expanded, Scopus)
  11. Patterns of Failure After Prostate-Only Radiotherapy in High-Risk Prostate Cancer: Implications for Refining Pelvic Nodal Contouring Guidelines in Regard to Singh et al.Onaly C., Elmaliy A., HÜRMÜZ P.CLINICAL ONCOLOGY, sa.9, 2024 (SCI-Expanded, Scopus)
  12. Evaluation of Treatment Outcomes of Prostate Cancer Patients With Lymph Node Metastasis Treated With Definitive RadiotherapyOnal C., Guler O. C., ERPOLAT Ö. P., HÜRMÜZ P., Sutera P., Deek M. P., et al.CLINICAL NUCLEAR MEDICINE, cilt.49, sa.8, 2024 (SCI-Expanded, Scopus)
  13. Prostate-Specific Membrane Antigen PET Response Associates with Metastasis-Free Survival After Stereotactic Ablative Radiation in Oligometastatic Prostate CancerSutera P., Deek M. P., Deek R. A., Guler O. C., HÜRMÜZ P., Reyhan M., et al.ADVANCES IN RADIATION ONCOLOGY, cilt.9, sa.7, 2024 (ESCI, Scopus)
  14. The Impact of Dose Rate on the Tumor Microenvironment Using Flattening-filter-free BeamsYILMAZ M., Gok A., Gedik M., ÇAĞLAYAN A., YEDEKÇİ F. Y., AYDIN DİLSİZ S., et al.Clinical Oncology, cilt.36, sa.6, ss.390-398, 2024 (SCI-Expanded, Scopus)
  15. Predicting Overall Survival for Patients Who Underwent Adjuvant Chemoradiotherapy for Gastric CancerYilmaz M. T., HÜRMÜZ P., DAĞ O., YİĞİT E., Ozyure Y., AVCI H., et al.RADIOTHERAPY AND ONCOLOGY, 2024 (SCI-Expanded, Scopus)
  16. A Post-International Gastrointestinal Cancers Conference (IGICC) Position Statements 'YALÇIN Ş., Lacin S., Kaseb A. O., PEYNİRCİOĞLU B., Cantasdemir M., ÇİL B. E., et al.JOURNAL OF HEPATOCELLULAR CARCINOMA, cilt.11, ss.953-974, 2024 (SCI-Expanded, Scopus)
  17. Radiation Oncologists' Approach to Rectosigmoid Junction Tumors in Turkey: The Turkish Society for Radiation Oncology Gastrointestinal Group Survey Study (TROD 02-007)AYNACI Ö., Serdar L., CANYILMAZ E., HÜRMÜZ P.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology, cilt.34, sa.9, ss.911-917, 2023 (SCI-Expanded, Scopus, TRDizin)
  18. In Regard to Zeng et al.Sari S. Y., KAHVECİOĞLU A., HÜRMÜZ P.International Journal of Radiation Oncology Biology Physics, cilt.116, sa.3, ss.690, 2023 (SCI-Expanded, Scopus)
  19. Stereotactic body radiotherapy and tyrosine kinase inhibitors in patients with oligometastatic renal cell carcinoma: a multi-institutional studyOnal C., Oymak E., Guler O. C., TİLKİ B., Yavas G., HÜRMÜZ P., et al.Strahlentherapie und Onkologie, cilt.199, sa.5, ss.456-464, 2023 (SCI-Expanded, Scopus)
  20. Treatment outcomes of postoperative ultra-hypofractionated stereotactic body radiotherapy in prostate cancerÖZYİĞİT G., Onal C., BEDÜK ESEN Ç. S., TİLKİ B., HÜRMÜZ P.Urologic Oncology: Seminars and Original Investigations, cilt.41, sa.5, 2023 (SCI-Expanded, Scopus)
  21. In regard to wandrey et alSari S., KAHVECİOĞLU A., HÜRMÜZ P.Lung Cancer, cilt.179, 2023 (SCI-Expanded, Scopus)
  22. The Effect of Video-Based Education on Anxiety of Patients Receiving Stereotactic Radiosurgery and Stereotactic Body Radiation TherapyBEDÜK ESEN Ç. S., YAZICI G., HÜRMÜZ P., ÖZYİĞİT G., Zorlu F.JOURNAL OF CANCER EDUCATION, cilt.38, sa.2, ss.426-430, 2023 (SCI-Expanded, Scopus)
  23. Planning and dosimetric evaluation of three total body irradiation techniques: Standard SSD VMAT, Extended SSD VMAT and Extended SSD Field-in-FieldCananoglu M., HÜRMÜZ P., YEĞİNER M., ÖZYİĞİT G.RADIATION AND ENVIRONMENTAL BIOPHYSICS, cilt.62, sa.1, ss.73-81, 2023 (SCI-Expanded, Scopus)
  24. Treatment Outcomes of Stereotactic Body Radiotherapy in Patients with Synchronous and Metachronous Oligometastatic Renal Cell CarcinomaGuler O. C., Oymak E., HÜRMÜZ P., Yavas G., TİLKİ B., Yavas C., et al.Urologia Internationalis, cilt.107, sa.2, ss.171-178, 2023 (SCI-Expanded, Scopus)
  25. Bone-only oligometastatic renal cell carcinoma patients treated with stereotactic body radiotherapy: a multi-institutional studyOnal C., Guler O. C., HÜRMÜZ P., YAVAŞ G., TİLKİ B., Oymak E., et al.STRAHLENTHERAPIE UND ONKOLOGIE, cilt.198, sa.10, ss.940-948, 2022 (SCI-Expanded, Scopus)
  26. The addition of pelvic lymph node treatment to prostate bed salvage radiotherapyKAHVECİOĞLU A., Yilmaz M. T., HÜRMÜZ P.The Lancet, cilt.400, sa.10356, ss.884-885, 2022 (SCI-Expanded, Scopus)
  27. The role of stereotactic body radiotherapy in switching systemic therapy for patients with extracranial oligometastatic renal cell carcinomaOnal C., HÜRMÜZ P., Guler O. C., YAVAŞ G., TİLKİ B., Oymak E., et al.CLINICAL & TRANSLATIONAL ONCOLOGY, cilt.24, sa.8, ss.1533-1541, 2022 (SCI-Expanded, Scopus)
  28. SABR for Oligametastatic DiseaseKilicoglu G. S., HÜRMÜZ P.INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, cilt.113, sa.3, ss.697, 2022 (SCI-Expanded, Scopus)
  29. Comments on "Whole lung irradiation as a novel treatment for COVID-19: Final results of the prospective randomized trial (WINCOVID trial)"ÖZYÜREK Y., Sari S., HÜRMÜZ P.RADIOTHERAPY AND ONCOLOGY, cilt.170, ss.244-245, 2022 (SCI-Expanded, Scopus)
  30. National Multi-Center Observational Retrospective Study to Understand Treatment Patterns and Outcomes for Stage III Non-Small Cell Lung Cancer Patients in Turkey: Turkish Society for Radiation Oncology Study, STONE TrialOnal C., DEMİRAL A. N., ATALAR B., YALMAN D., Dagoglu N., HÜRMÜZ P., et al.UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI, cilt.32, sa.1, ss.23-34, 2022 (SCI-Expanded, Scopus, TRDizin)
  31. Definitive Chemoradiotherapy Results in Synchronous Oligometastatic Non-small Cell Lung Cancer Patients Turkish Society for Radiation Oncology Group Study (TROD 10-003)DURU BİRGİ S., Akgun Z., HÜRMÜZ P., AKYÜREK S., Saglam E. K., YILMAZ M. T., et al.AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, cilt.45, sa.1, ss.40-47, 2022 (SCI-Expanded, Scopus)
  32. Considerations for Clinical Trials Testing Radiotherapy Combined With Immunotherapy for Metastatic DiseaseSezen D., Verma V., He K., Abana C. O., Barsoumian H., Ning M. S., et al.SEMINARS IN RADIATION ONCOLOGY, cilt.31, sa.3, ss.217-226, 2021 (SCI-Expanded, Scopus)
  33. Oligometastatic Bone Disease in Castration-Sensitive Prostate Cancer Patients Treated With Stereotactic Body Radiotherapy Using Ga-68-PSMA PET/CT TROD 09-004 StudyOnal C., ÖZYİĞİT G., Akgun Z., Atalar B., Igdem S., Oymak E., et al.CLINICAL NUCLEAR MEDICINE, cilt.46, sa.6, ss.465-470, 2021 (SCI-Expanded, Scopus)
  34. Gemcitabine based trimodality treatment in patients with muscle invasive bladder cancer: May neutrophil lymphocyte and platelet lymphocyte ratios predict outcomes?HÜRMÜZ P., ÖZYİĞİT G., Kilickap S., BEDÜK ESEN Ç. S., AKDOĞAN B., Ozen H., et al.UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, cilt.39, sa.6, 2021 (SCI-Expanded, Scopus)
  35. Factors affecting post-treatment radiation-induced lung disease in patients receiving stereotactic body radiotherapy to lungHÜRMÜZ P., CENGİZ M., Esen C. S. B., Yedekci Y., YILDIZ Z., ÖZYİĞİT G., et al.Radiation and Environmental Biophysics, cilt.60, ss.87-92, 2021 (SCI-Expanded, Scopus)
  36. Neoadjuvant Radiotherapy in Rectal Cancer: A Single Center ExperienceHÜRMÜZ P., TİLKİ B., CENGİZ M., YILDIZ F., ÖZYİĞİT G., EROL T., et al.UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI, cilt.31, sa.3, ss.178-184, 2021 (SCI-Expanded, Scopus, TRDizin)
  37. Does Intravesical Prostatic Protrusion Affect Oncological Outcomes and Toxicity in Prostate Cancer Patients Receiving Definitive Radiotherapy?HÜRMÜZ P., BEDÜK ESEN Ç. S., Unal E., KARÇAALTINCABA M., ÖZYİĞİT G., AKYOL H. F.UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI, cilt.31, sa.1, ss.1-7, 2021 (SCI-Expanded, Scopus, TRDizin)
  38. Hyaluronic acid spacer in focal prostate reirradiation: A single centre experienceÖZYİĞİT G., HÜRMÜZ P., AKINCI D., Esen S. C. B., YILMAZ M., AKDOĞAN B., et al.CANCER RADIOTHERAPIE, cilt.24, sa.8, ss.805-811, 2020 (SCI-Expanded, Scopus)
  39. Treatment outcomes of metastasis-directed treatment using(68)Ga-PSMA-PET/CT for oligometastatic or oligorecurrent prostate cancer: Turkish Society for Radiation Oncology group study (TROD 09-002)HÜRMÜZ P., Onal C., ÖZYİĞİT G., Igdem S., Atalar B., Sayan H., et al.STRAHLENTHERAPIE UND ONKOLOGIE, cilt.196, sa.11, ss.1034-1043, 2020 (SCI-Expanded, Scopus)
  40. Role of 68-Ga-PSMA-PET/CT in pelvic radiotherapy field definitions for lymph node coverage in prostate cancer patientsOnal C., Ozyigit G., Cem G., Hurmuz P., Torun N., Tuncel M., et al.RADIOTHERAPY AND ONCOLOGY, cilt.151, ss.222-227, 2020 (SCI-Expanded, Scopus)
  41. Stereotactic body radiotherapy in patients with early-stage non-small cell lung cancer: Does beam-on time matter?HÜRMÜZ P., CENGİZ M., ÖZYİĞİT G., Akkas E. A., YÜCE D., YILMAZ M. T., et al.JAPANESE JOURNAL OF CLINICAL ONCOLOGY, cilt.50, sa.10, ss.1182-1187, 2020 (SCI-Expanded, Scopus)
  42. FLASH-radiotherapy: A new perspective in immunotherapy era?YILMAZ M. T., HÜRMÜZ P., YAZICI G.RADIOTHERAPY AND ONCOLOGY, cilt.145, ss.137, 2020 (SCI-Expanded, Scopus)
  43. Comments on "Risk factors for vertebral compression fracture after spine stereotactic body radiation therapy: Long-term results of a prospective phase 2 study"YILMAZ M. T., HÜRMÜZ P.RADIOTHERAPY AND ONCOLOGY, cilt.145, ss.127, 2020 (SCI-Expanded, Scopus)
  44. Hypofractionated radiotherapy for non-metastatic bone and soft tissue sarcomasSARI S., CENGİZ M., Dauletkazin A., YAZICI G., GÜLTEKİN M., HÜRMÜZ P., et al.CANCER RADIOTHERAPIE, cilt.23, sa.8, ss.853-859, 2019 (SCI-Expanded, Scopus)
  45. Treatment outcomes of prostate cancer patients with Gleason score 8-10 treated with definitive radiotherapyÖZYİĞİT G., Onal C., Igdem S., Alicikus Z. A., Iribas A., Akin M., et al.STRAHLENTHERAPIE UND ONKOLOGIE, cilt.195, sa.10, ss.882-893, 2019 (SCI-Expanded, Scopus)
  46. Integration of 68Ga-PSMA-PET/CT in Radiotherapy Planning for Prostate Cancer PatientsOnal C., Torun N., Akyol F., Guler O. C., HÜRMÜZ P., Yildirim B. A., et al.CLINICAL NUCLEAR MEDICINE, cilt.44, sa.9, 2019 (SCI-Expanded, Scopus)
  47. Prognostic significance of castrate testosterone levels for patients with intermediate and high risk prostate cancerÖZYİĞİT G., HÜRMÜZ P., YÜCE D., Akyol F.WORLD JOURNAL OF CLINICAL ONCOLOGY, cilt.10, sa.8, ss.283-292, 2019 (ESCI)
  48. Long Term Follow-Up on NRG Oncology RTOG 0915 (NCCTG N0927): A Randomized Phase II Study Comparing 2 Stereotactic Body Radiation Therapy Schedules for Medically Inoperable Patients With Stage I Peripheral Non-Small Cell Lung Cancer In Regard to Videtic et alYILMAZ M. T., HÜRMÜZ P., CENGİZ M.INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, cilt.104, sa.2, ss.466-467, 2019 (SCI-Expanded, Scopus)
  49. Sub-Castrate Testosterone Nadir and Clinical Outcomes in Intermediate or High-Risk Localized Prostate CancerHÜRMÜZ P., ÖZYİĞİT G.INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, cilt.104, sa.1, ss.224-225, 2019 (SCI-Expanded, Scopus)
  50. A Phase II Study of Stereotactic Body Radiation Therapy and Stereotactic Body Proton Therapy for High-risk Medically Inoperable Early-stage Non-small Cell Lung CancerHÜRMÜZ P., ÖZYİĞİT G.INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, cilt.101, sa.3, ss.744-745, 2018 (SCI-Expanded, Scopus)
  51. Concurrent Immune Checkpoint Inhibitors and Radiation TherapyYILMAZ M. T., HÜRMÜZ P., CENGİZ M.INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, cilt.101, sa.4, ss.998, 2018 (SCI-Expanded, Scopus)
  52. Update of a Prospective Study of Stereotactic Body Radiation Therapy for Post-Chemoradiation Residual Disease in Stage II/III Non-Small Cell Lung CancerHÜRMÜZ P., CENGİZ M., Zorlu F., Akyol F.INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, cilt.100, sa.4, ss.1079-1080, 2018 (SCI-Expanded, Scopus)
  53. Küçük Hücreli Dışı Akciğer Kanserlerinde Definitif KemoradyoterapiYÜCE SARI S., HÜRMÜZ P., AKYOL H. F.Türkiye Klinikleri Radyasyon Onkolojisi Özel Dergisi, cilt.4, sa.1, ss.52-59, 2018 (TRDizin)
  54. Investigating the surface dose contribution of intrafractional kV imaging in CyberKnife-based stereotactic radiosurgeryCanbolat A., Zorlu F., HÜRMÜZ P., YEĞİNER M., ÖZYİĞİT G.MEDICAL DOSIMETRY, cilt.42, sa.4, ss.304-309, 2017 (SCI-Expanded, Scopus)
  55. Reirradiation of Pediatric Tumors Using Hypofractionated Stereotactic Radiotherapy.GULTEKIN M., CENGIZ M., SEZEN D., ZORLU F., YILDIZ F., Yazici G., et al.Technology in cancer research & treatment, cilt.16, ss.195-202, 2017 (SCI-Expanded, Scopus)
  56. Prevalence of Complementary Medicine Use in Patients With Cancer: A Turkish Comprehensive Cancer Center ExperienceYALÇIN Ş., HÜRMÜZ P., McQuinn L., Naing A.JOURNAL OF GLOBAL ONCOLOGY, cilt.4, 2017 (ESCI, Scopus)
  57. The dosimetric impact of implants on the spinal cord dose during stereotactic body radiotherapyYAZICI G., SARI S., YEDEKÇİ F. Y., Yucekul A., BIRGI S. D., DEMIRKIRAN G., et al.RADIATION ONCOLOGY, cilt.11, 2016 (SCI-Expanded, Scopus)
  58. Robotic Stereotactic Body Radiation Therapy in Patients With Recurrent or Metastatic Abdominopelvic Tumors: A Single Institute ExperienceSezen D., GÜRKAYNAK H. M., GÜLTEKİN M., CENGİZ M., YILDIZ F., ZORLU A. F., et al.TECHNOLOGY IN CANCER RESEARCH & TREATMENT, cilt.15, sa.1, ss.203-211, 2016 (SCI-Expanded, Scopus)
  59. Evaluation of the Effect of Changes in Dose Rate on Rat Lung CellsHÜRMÜZ P., KIVANC H., CANBOLAT A., Yavas G., YÜCE D., ÖNDER S. Ç., et al.TECHNOLOGY IN CANCER RESEARCH & TREATMENT, cilt.14, sa.3, ss.343-349, 2015 (SCI-Expanded, Scopus)
  60. Three Dimensional Conformal Radiotherapy and Androgen Deprivation Therapy in Patients with Clinically Localized Prostate Cancer; Hacettepe University ExperienceÖZDEMİR Y., Akyol F., ÖZYİĞİT G., HÜRMÜZ P., Onal C., Selek U., et al.UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI, cilt.25, sa.2, ss.107-117, 2015 (SCI-Expanded, Scopus, TRDizin)

AVESİS'te 76 kaydın tamamı →

Hakemli Bilimsel Toplantılarda Yayımlanmış Bildiriler 16

  1. Plevra kaynakli kistik Ewing sarkoma olgusu ve literatür taraması.YAMAN BAJİN H. İ., KURUCU N., OĞUZ B., AYDIN G. B., ORHAN D., EKİNCİ S., et al.TPOG 2018 XX. Ulusal Pediatrik Kanser Kongresi, Türkiye, 2 - 06 Mayıs 2018, (Özet Bildiri)
  2. Cyberknife Robotik Cerrahi Ünitesinin Mekanik Stabilitesinin Analiz EdilmesiBİLTEKİN F., Eken S., Yücel H., YEĞİNER M., HÜRMÜZ P., DOĞAN A., et al.11. Ulusal Radyasyon Onkolojisi Kongresi, Antalya, Türkiye, 23 - 27 Nisan 2014, cilt.29, ss.334, (Özet Bildiri)
  3. Aksiyal ve helikal bilgisayarli tomografi taramalarindan kaynakli organ esdeger dozlarinin karsilastirilmasiYILDIZ D., DÜĞEL G., BİLTEKİN F., YÜREKLİ A. F., GHALION B. K., ŞİŞECİOĞLU S., et al.10. Ulusal Radyasyon Onkolojisi Kongresi, Antalya, Türkiye, 19 - 23 Nisan 2012, (Özet Bildiri)
  4. Pencil beam convolution (PBC) algoritmasi ile hesaplanan doz degerlerinin Alderson rando fantomda alinan olcum sonuclari ile karsilastirilmasiBİLTEKİN F., ÇELİK D., YÜCE SARI S., ABDELKADER A., GHALION B. K., YÜREKLİ A. F., et al.10. Ulusal Radyasyon Onkolojisi Kongresi, Antalya, Türkiye, 19 - 23 Nisan 2012, (Özet Bildiri)
  5. Radyoterapi uygulamalarinda yuksek enerjili foton ve elektron demetlerinin kullanimi sirasinda tedavi odasinda sacilmalardan kaynakli doz degerlerinin olculmesiBİLTEKİN F., ÇELİK D., GHALION B. K., ABDELKADER A., YÜREKLİ A. F., ŞİŞECİOĞLU S., et al.10. Ulusal Radyasyon Onkolojisi Kongresi, Antalya, Türkiye, 19 - 23 Nisan 2012, (Özet Bildiri)
  6. Treatment outcomes of metastasis-directed treatment using 68 Ga-PSMA-PET/CT for oligometastatic or oligorecurrent prostate cancer: Turkish Society for Radiation Oncology group study (TROD 09-002)HÜRMÜZ P., ÖNAL H. C., ÖZYİĞİT G., İĞDEM M. Ş., ATALAR B., sayan h., et al.
  7. Gleason skoru 10 prostat kanserierinde definif radyoterapi ve ADT sonuçları: TROD09-001 ÜRO- ONKOLOJİ GRUBU ÇALıŞMASIHÜRMÜZ P., ÖNAL H. C., İribaş A., ALSAN ÇETİN İ., Akbulut S., GÖRKEN İ., et al.
  8. Evaluation of Prognostic Biomarkers in Stage III Non-Small Cell Lung Cancer Turkish Radiation Oncology Group Lung Cancer Studying GroupGÜMÜŞTEPE E., YAVAŞ G., korkaz kıraklı e., YILMAZ M. T., ÖZLER T., HÜRMÜZ P., et al.
  9. Interpreting Clinical Parameters and Nomograms for Predicting Lymph Node Metastasis Detected with 68 Ga-PSMAPET/CT in prostate cancer patientsÖNAL H. C., ÖZYİĞİT G., Oymak E., GÜLER O. C., HÜRMÜZ P., TİLKİ B., et al.
  10. Evaluation of Prognostic Biomarkers in Stage III Non-Small Cell Lung Cancer Turkish Radiation Oncology Group Lung Cancer Studying GroupGÜMÜŞTEPE E., YAVAŞ G., Kirakli E. K., YILMAZ M. T., Özler T., HÜRMÜZ P., et al.
  11. Definitive Chemoradiotherapy in Esophageal Squamous Cell Cancer: A Single Center ExperienceYILMAZ M. T., HÜRMÜZ P., CENGİZ M., YÜCE D., ZORLU A. F., AKYOL H. F., et al.
  12. the role of neoadjuvant radiotherapy in rectal cancer: hacettepe university experienceHÜRMÜZ P., TİLKİ B., YILDIZ F., ÖZYİĞİT G., EROL T., KONAN A., et al.
  13. DEFİNİTİVE CHEMORADİOTHERAPY İN ESOPHAGEAL S@UAMOUS CELL CANCER A SİNGLE CENTER EXPERİENCEHÜRMÜZ P., CENGİZ M., YÜCE D., ZORLU A. F., AKYOL H. F., YALÇIN Ş., et al.
  14. non-operative management of rectal cancer: hacettepe university experienceTİLKİ B., HÜRMÜZ P., CENGİZ M., ZORLU A. F., ÖZYİĞİT G., YILDIZ F., et al.
  15. National, Observational, Multicentric Study in Stage III Non-Small Cell Lung Cancer Patients in Turkey: Stone TrialÖNAL H. C., ATALAR B., DEMİRAL A. N., YALMAN D., Gül Ş., HÜRMÜZ P., et al.
  16. The Role of (68)ga-PSMA-PET/CT in Pelvic FIELD Delineation in Prostate Cancer Patients with Pelvic Lymph Node MetastasisOnal C., HÜRMÜZ P., Torun N., TUNCEL M., Guler O. C., Reyhan M., et al.

Kitaplar 23

  1. SarcomaYÜCE SARI S., YAZICI G., GÜLTEKİN M., HÜRMÜZ P., GÜRKAYNAK H. M., ÖZYİĞİT G.Radiation Oncology: A Case Based Review, Gokhan Ozyigit, Ugur Selek, Editör, Springer International Publishing, Cham, ss.405-458, 2018
  2. Gastrointestinal System CancersHÜRMÜZ P., YAZICI G., GÜLTEKİN M., YÜCE SARI S., CENGİZ M., ÖZYİĞİT G.Radiation Oncology: A Case-Based Review, Gokhan Ozyigit, Ugur Selek, Editör, Springer International Publishing, Cham, ss.203-274, 2018
  3. Central Nervous System TumorsYAZICI G., GÜLTEKİN M., HÜRMÜZ P., YÜCE SARI S., ZORLU A. F., ÖZYİĞİT G.Radiation Oncology: A Case-Based Review, Gokhan Ozyigit, Ugur Selek, Editör, Springer International Publishing, Cham, ss.11-51, 2018
  4. Gynecological CancersGÜLTEKİN M., YÜCE SARI S., YAZICI G., HÜRMÜZ P., YILDIZ F., ÖZYİĞİT G.Radiation Oncology: A Case Based Review, Gokhan Ozyigit, Ugur Selek, Editör, Springer Nature, Cham, ss.314-404, 2018
  5. Genitourinary System CancersÖZYİĞİT G., HÜRMÜZ P., YÜCE SARI S., ÖNAL H. C., BİLTEKİN F., GÜLTEKİN M., et al.Radiation Oncology: A Case Based Review, Gokhan Ozyigit, Ugur Selek, Editör, Springer Nature Publishing, Cham, ss.275-313, 2018
  6. Stereotactic Body Radiotherapy for Prostate CancerAKYOL H. F., YAZICI G., GÜLTEKİN M., HÜRMÜZ P., YÜCE SARI S., ÖZYİĞİT G.Principles and Practice of Urooncology, Gökhan Özyiğit, Uğur Selek, Editör, Springer, 2017
  7. PSA After Radiotherapy: PSA Bounce and Biochemical FailureAKYOL H. F., GÜLTEKİN M., YAZICI G., HÜRMÜZ P., YÜCE SARI S., ÖZYİĞİT G.Principles and Practice of Urooncology, Gökhan Özyiğit, Uğur Selek, Editör, Springer, 2017
  8. Guidelines for the Delineation of Primary Tumor Target Volume in Prostate CancerYAZICI G., YÜCE SARI S., HÜRMÜZ P., GÜLTEKİN M., AKYOL H. F., ÖZYİĞİT G.Principles and Practice of Urooncology, Gökhan Özyiğit, Uğur Selek, Editör, Springer, 2017
  9. Radiation-Induced Toxicity and Related Management Strategies in Urological MalignanciesYÜCE SARI S., GÜLTEKİN M., HÜRMÜZ P., YAZICI G., AKYOL H. F., ÖZYİĞİT G.Principles and Practice of Urooncology, Gökhan Özyiğit, Uğur Selek, Editör, Springer, 2017
  10. Target Volume Delineation Guidelines in Bladder CancerGÜLTEKİN M., YÜCE SARI S., HÜRMÜZ P., YAZICI G., AKYOL H. F., ÖZYİĞİT G.Principles and Practice of Urooncology, Gökhan Özyiğit, Uğur Selek, Editör, Springer, 2017
  11. Guidelines for the Delineation of Lymphatic Target Volumesin Prostate CancerÖZYİĞİT G., YAZICI G., YÜCE SARI S., GÜLTEKİN M., HÜRMÜZ P., AKYOL H. F.Principles and Practice of Urooncology, Gökhan Özyiğit, Uğur Selek, Editör, Springer, 2017
  12. The Role of Hormonal Treatment in Prostate CancerHÜRMÜZ P., AKYOL H. F., GÜLTEKİN M., YAZICI G., YÜCE SARI S., ÖZYİĞİT G.Principles and Practice of Urooncology, Gökhan Özyiğit, Uğur Selek, Editör, Springer, 2017
  13. Guidelines for the delineation of lymphatic target volumes in lung cancerÖZYİĞİT G., GÜLTEKİN M., YÜCE SARI S., YAZICI G., HÜRMÜZ P.Principles and Practice of Radiotherapy Techniques in Thoracic Malignancies, Gökhan Özyiğit, Uğur Selek, Erkan Topkan, Editör, Springer, 2016
  14. Stereotactic Ablative Radiotherapy for lung cancerÖZYİĞİT G., YÜCE SARI S., YAZICI G., HÜRMÜZ P., GÜLTEKİN M.Principles and Practice of Radiotherapy Techniques in Thoracic Malignancies, Gökhan Özyiğit, Uğur Selek, Erkan Topkan, Editör, springer, 2016
  15. Target volume delineation guidelines in malignant pleural mesotheliomaÖZYİĞİT G., HÜRMÜZ P., YÜCE SARI S., YAZICI G., GÜLTEKİN M.Principles and Practice of Radiotherapy Techniques in Thoracic Malignancies, Gökhan Özyiğit, Uğur Selek, Erkan Topkan, Editör, Springer, 2016
  16. Radiation- induced toxicities and management strategies in thoracic malignanciesÖZYİĞİT G., YAZICI G., YÜCE SARI S., GÜLTEKİN M., HÜRMÜZ P.Principles and Practice of Radiotherapy Techniques in Thoracic Malignancies, Gökhan Özyiğit, Uğur Selek, Erkan Topkan, Editör, Springer, 2016
  17. Modern radiotherapy techniques in malignant pleural mesotheliomaÖZYİĞİT G., HÜRMÜZ P., YÜCE SARI S., YAZICI G., GÜLTEKİN M.Principles and Practice of Radiotherapy Techniques in Thoracic Malignancies, Gökhan Özyiğit, Ugur Selek, Erkan Topkan, Editör, Springer, 2016
  18. Guidelines for the delineation of primary tumor target volume in lung cancerÖZYİĞİT G., GÜLTEKİN M., YÜCE SARI S., HÜRMÜZ P., YAZICI G.Principles and Practice of Radiotherapy Techniques in Thoracic Malignancies, Gokhan Ozyigit, Ugur Selek, Erkan Topkan, Editör, Springer, Houston, ss.39-50, 2016
  19. Radyoterapi ve COVID-19HÜRMÜZ P., ÖZYİĞİT G.
  20. Toxicity Management for Head and Neck Tumors in Radiation Oncology-IIHÜRMÜZ P.
  21. Nasal cavity and paranasal sinusesYAZICI G., SARI s., CENGİZ M., HÜRMÜZ P., GÜLTEKİN M., ÖZYİĞİT G.
  22. Salivary glandGÜLTEKİN M., SARI S., ÖZYİĞİT G., CENGİZ M., YAZICI G., HÜRMÜZ P., et al.
  23. Oral cavitySARI S., ÖZYİĞİT G., GÜLTEKİN M., YAZICI G., HÜRMÜZ P., CENGİZ M., et al.

İletişim

Telefon
0312 305 29 00
Bölüm
Radyasyon Onkolojisi, Onkoloji Hastanesi
Konuştuğu diller
İngilizce

Son güncelleme: